{"filing":{"accession_number":"0001213900-26-079678","cik":"0002028614","ticker":"DMAAR","company_name":"Drugs Made In America Acquisition Corp.","form":"8-K","filing_date":"2026-07-20","report_date":null,"primary_document":"ea0298461-8k425_drugs.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2028614/000121390026079678/ea0298461-8k425_drugs.htm"},"events":[{"id":18860,"run_id":16964,"accession_number":"0001213900-26-079678","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"This disclosure reports Amendment No. 3 to a material definitive merger agreement between DMAA and Power Analytics Global Corp (PAGC), approved by both boards on July 14, 2026. The amendment modifies key terms of the business combination including founder share treatment, rights treatment, merger consideration calculation, minimum cash provisions, and related-party protections. This constitutes a material amendment to an entry into a material definitive agreement under Item 1.01, directly affecting the terms and conditions of the contemplated merger transaction.","company_name":"Drugs Made In America Acquisition Corp.","ticker":"DMAAR","filing_date":"2026-07-20","form":"8-K","submitted_at":null,"items":[{"id":17800,"accession_number":"0001213900-26-079678","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"This disclosure reports Amendment No. 3 to a material definitive merger agreement between DMAA and Power Analytics Global Corp (PAGC), approved by both boards on July 14, 2026. The amendment modifies key terms of the business combination including founder share treatment, rights treatment, merger consideration calculation, minimum cash provisions, and related-party protections. This constitutes a material amendment to an entry into a material definitive agreement under Item 1.01, directly affecting the terms and conditions of the contemplated merger transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T21:01:46.606815+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17800,"accession_number":"0001213900-26-079678","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"This disclosure reports Amendment No. 3 to a material definitive merger agreement between DMAA and Power Analytics Global Corp (PAGC), approved by both boards on July 14, 2026. The amendment modifies key terms of the business combination including founder share treatment, rights treatment, merger consideration calculation, minimum cash provisions, and related-party protections. This constitutes a material amendment to an entry into a material definitive agreement under Item 1.01, directly affecting the terms and conditions of the contemplated merger transaction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-20T21:01:46.606815+00:00","company_name":"Drugs Made In America Acquisition Corp.","ticker":"DMAAR","filing_date":"2026-07-20"}]}